GeneticTechnologies BREVAGen Brustkrebsrisiko Test
| eröffnet am: | 28.04.11 13:58 von: | ticketman27 |
| neuester Beitrag: | 25.04.21 02:21 von: | Christineobnra |
| Anzahl Beiträge: | 78 | |
| Leser gesamt: | 26154 | |
| davon Heute: | 3 | |
bewertet mit 2 Sternen |
||
|
|
||
09/05/2012 Settlement with GeneSeek
http://www.asx.com.au/asxpdf/20120509/pdf/42653xdm9syf2q.pdf
22/05/2012 BREVAGen credentialing update
http://www.asx.com.au/asxpdf/20120522/pdf/426dgtmp0hrb00.pdf
30/05/2012 Appendix 3B
http://www.asx.com.au/asxpdf/20120530/pdf/426kd561m3dlt9.pdf
http://www.asx.com.au/asxpdf/20120709/pdf/4279vp256ygszg.pdf
Das Seminar über BREVAGen und Brustkrebs Risikobewertung findet am Freitag, 17 August, 2012 von 12.30 Uhr bis 02.00 Uhr in The Woodlands Institut für Gesundheit und Wellness in 26110 Oak Ridge Drive, The Woodlands, Texas. Alle Interessierten, die mehr über Brustgesundheit und BREVAGen ist herzlich eingeladen.
Local Physician One Of The First In Nation To Use New Breast Cancer Predictive Risk Test
THE WOODLANDS, Texas--(BUSINESS WIRE)--Dr. Mila McManus of The Woodlands Institute for Health and Wellness, one of the first physicians in the nation to make the BREVAGen™ predictive risk test available to her patients, is conducting a free community seminar on August 17, 2012 to introduce BREVAGen and discuss its importance in breast cancer risk assessment. Clinically validated, BREVAGen is the latest advance in assessing a woman’s unique risk of developing non-familial or sporadic breast cancer, which accounts for 70 to 80 percent of all breast cancer cases.
...wie man sieht,der Test startet erst jetzt so richtig,immerr noch Zeit in Genetic Techn. zu investieren!
so long!
TM
MELBOURNE, AUSTRALIA -- (Marketwire) -- 07/26/12 -- Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the Laboratory Field Services Unit of the California Department of Public Health (CDPH) has granted a license to the Company's Australian-based laboratory. BREVAGen™ may now be offered forhe State of C sale into talifornia.
Based solely on incidence rates, California represents approximately 11% of the United States' total breast cancer incidents, with over 25,000 new cases of breast cancer diagnosed annually. (ACS Breast Cancer Facts & Figures 2011-12, ACS Cancer Facts & Figures 2012)
We expect Califoro be a large and significant market for BREVAGen™," said Dr. Paul MacLeman, Genetic Technologies' Chief Executive Officer. "We will be applying sales and marketing resources to drive test adoption and sales in the State in the coming weeks."
U.S. State Certification
In April 2011, Genetic Technologies successfully attained CLIA approval, allowing BREVAGen™ to be sold into 42 U.S. States (see ASX announcement dated April 27th, 2011). Following the Company's receipt of a certificate of compliance issued by the Centers for Medicare and Medicaid Services (see ASX announcement dated February 16th, 2012), the Company has submitted numerous applications for "Out of State Licensure," which allow BREVAGen™ to also be sold in Pennsylvania, Rhode Island, Nevada, Tennessee, Maryland, and now in California. The Company has also submitted a licensure application in Florida and expects to receive approval to sell BREVAGen™ in this key State shortly.
The Company has commenced serial submission of an application to submit to the New York State Department of Health, Clinical Laboratory Evaluation Program (CLEP) to offer Out of State Clinical Lab Services to New York State residents.
http://www.asx.com.au/asxpdf/20120724/pdf/427kc5pcr21w2p.pdf
und wie vom Ticketman schon erwähnt..
26/07/2012 BREVAGen cleared for sale in California
http://www.asx.com.au/asxpdf/20120726/pdf/427lrvt2fwbyht.pdf
http://www.asx.com.au/asxpdf/20120730/pdf/427ntxtb0cfw74.pdf
August 8, 2012
Genetic Technologies Receives CE Mark Approval for BREVAGen™
Melbourne, Australia; August 8, 2012: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE)
announced today that it has received European CE Mark approval for BREVAGen™, the Company’s
breast cancer risk test. The CE Mark designation will allow BREVAGen™ to be sold in the EU and
other countries that recognise the CE Mark. The initial commercial focus will be in the key markets of
France and Germany.
Breast cancer is the most common form of cancer in European women. In 2008, annual breast cancer
incidence in the European Union (EU-27) was over 330,000. This is nearly double the incidence rate in
the U.S. of just over 180,000 cases per year (cited electronically at http://globocan.iarc.fr/). Approximately 80%
of women who develop breast cancer develop non-familial or sporadic breast cancer, that is, they have
little or no family history of the disease.
“The achievement of CE Mark for our flagship BREVAGen™ product is a major milestone for the
Company,” stated Dr. Paul MacLeman, CEO of Genetic Technologies. “Given the significant incidence
rate of breast cancer in the EU, there is a critical need for enhanced risk assessment tools, leading to
improved preventative management and surveillance.”
BREVAGen™ uses a novel approach to non-familial breast cancer risk assessment, combining validated
breast cancer susceptibility genetic markers with a patient’s individual clinical risk factors to yield an
integrated, more accurate risk score. The test was launched in June 2011 in select regions in the U.S.
and is currently available in 48 U.S. States.
CE Marking
Conformité Européenne, meaning European conformity, is a mandatory conformity mark for certain
products placed on market in the European Economic Area including medical devices and IVD tests.
CE Marking ensures that the manufacturer’s product conforms to the essential requirements of the
relevant European health, safety and environmental protection legislation. IVD tests, in accordance with
the EU directive 98/79/EC for IVDD, must be safe and function as per the manufacturer’s intended
purpose. BREVAGen’s™ CE Marking certification was conducted by MT Promedt Consulting GmbH,
a globally recognised European Authorized Representative with offices in Germany and the U.S.
ENDS
FOR FURTHER INFORMATION PLEASE CONTACT
Dr. Paul D.R. MacLeman Rudi Michelson (Australia) Laura Landry (USA)
Chief Executive Officer Monsoon Communications BluePrint Life Science Group
Genetic Technologies Limited +61 3 9620 3333 +1 (415) 375.3340 Ext. 2022
Phone: +61 3 8412 7000
Based solely on incidence rates, California represents approximately 11% of the United States total breast cancer incidents, with over 25,000 new cases of breast cancer diagnosed annually. (ACS Breast Cancer Facts & Figures 2011-12, ACS Cancer Facts & Figures 2012)
We expect California to be a large and significant market for BREVAGen™, said Dr. Paul MacLeman, Genetic Technologies Chief Executive Officer. We will be applying sales and marketing resources to drive test adoption and sales in the State in the coming weeks.
Another stock that’s quickly moving within range of triggering a near-term breakout trade is Genetic Technologies (GENE), which provides genetic testing services. This stock is off to a strong start in 2013, with shares up sharply by 24%.
If you look at the chart for Genetic Technologies, you’ll notice that this stock has been uptrending strong for the last two months, with shares moving higher from its low of $2.10 to its recent high of $2.90 a share. During that uptrend, shares of GENE have been consistently making higher lows and higher highs, which is bullish technical price action. That move has quickly pushed shares of GENE within range of triggering a near-term breakout trade.
Market players should now look for long-biased trades in GENE if it manages to break out above some near-term overhead resistance levels at $2.75 to $2.80 a share and then once it takes out more resistance at $2.90 to its 200-day at $3.14 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 38,979 shares. If that breakout triggers soon, then GENE will set up to re-test or possibly take its next major overhead resistance levels at $3.40 to $3.80 a share. Any high-volume move above those levels will then put $3.95 to $4.22 into range for shares of GENE.
Traders can look to buy GENE off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $2.47 a share or around more support at $2.36 a share. One can also buy GENE off strength once it clears those breakout levels with volume and then simply use a stop that sits right below its 50-day at $2.47 a share. I would add to either position once GENE clears its 200-day at $3.14 a share with heavy upside volume.
Sie sind am fernen Horizont, wohlgemerkt, aber es gibt Grund zur Hoffnung.
Genetic Technologies hat kürzlich angekündigt, dass sechs weitere Brustkrebsdiagnostik in Behandlungszentren w.gestartet, mit den BREVAgen Diagnose-Tool. Jedes Mal, dass Tally steigt, ist schrittweise höhere Umsätze auf dem Weg.
Während all das ist die Grundlage für Optimismus, das Potential des Tests ist nicht der Hauptgrund, als Investor möchten Sie vielleicht GENE über eine Beteiligung an einem Konkurrenten Unternehmen wie Hologic oder Quest Diagnostics wählen... Grund genug Genetic Technologies zu kaufen ist im Moment, dass es technisch aus einem Abwärtstrend aufsteigt und den Startschuss für einen Aufwärtstrend anzeigt.
Mal gucken. GENE steigt über die 100-Tage-Linie,jeder Schritt über die 200-Tage-Linie ist ein Katalysator. Unabhängig davon, welche Linien überschritten wurden oder nicht, wenn es sie überquert, ist der Paradigmenwechsel deutlich.
Es gibt nicht so etwas wie eine Garantie an der Wall Street. Aus Risiko-versus-Belohnung Sicht mit der Action in den letzten Tagen ist Genetic Technologies Limited eine hohe Belohnung mit nur einem bescheidenen Maß an Risiko. Es ist sicherlich eine überzeugendere Risiko- / Ertragssituation als Quest Diagnostics und Hologic sie zu diesem Zeitpunkt serviert...
http://www.smallcapnetwork.com/...a/1789/article/view/p/mid/3/id/602/
http://www.asx.com.au/asx/statistics/...isplay=pdf&idsId=01596930
gtg.jpg (verkleinert auf 31%)
January 20, 2015 Securities & exchange Commission 450 Fifth Street, NW Washington, DC 20549 Attn.: Document Control
RE:American Depositary Receipts representing thirty deposited shares of Genetic Technologies Limited. The Prospectus has beenrevised to reflect the new ratio, which has been changed to read: “Each American Depositary Share representsone hundred fifty deposited Shares”. The Bank of New York Mellon - ADR Division
Genetic Technologies Ltd (GTG.AX)
ASX
0.0680 Up 0.0180(36.00%) 16 Feb 16:10
GENE
Genetic Technologies Ltd Stock Quote & Summary Data
$8.04 Exchange: NASDAQ
*
1.90
30.94%
*Delayed - data as of Feb. 13, 2015
Read more: http://www.nasdaq.com/symbol/gene#ixzz3RuqVrEX4
chart.png (verkleinert auf 45%)
Nov 23, 2015 4:09 AM | about stocks: GENE
If you haven't been following the news that's been circulating lately around Genetic Technologies Limited, then read along.
As of November 17th, 2015, DB filed a Form 603, and declared themselves a substantial holder with 579,200 ADRs. Let's clear up some of this noise, there is a lot of misleading information floating around social media.
ADR: American Depository Receipt, is one of the most convenient and popular ways to buy stocks of companies based overseas. This is exactly what DB did on November 17th. The 579,200 ADR's is equivalent to 86,880,000 ordinary shares under U.S. dollars. This also gives DB the voting power of 5.07%.
So why should investors care?
Genetic Technologies Limited (NASDAQ:GENE): With a less than impressive balance sheet, and the reputation for burning capital at an excessive rate, just got a substantial holder from DB? Why would DB be risking a stake in such a speculative company?
News: This transaction comes off the heals of a insider transaction of the CEO. Furthermore, earlier on November 2, 2015, Phenogen Sciences, Inc (U.S. subsidiary of Australia-based Genetic Technologies and maker of BrevaGenplus) commented on the American Cancer Society's (ACS) recent breast cancer screening guidelines, which plays directly in favor of BrevaGenplus. The company makes it clear they are ready to solve this clinical gray area, and offered some guidance on how their product can solve this new protocol from the ACS.
Speculative pharmaceuticals are typically known for their cash burning capabilities and their low ROI on investment returns. Although, once and awhile these sleeping giants can reward those shareholders who do their due diligence of their homework on these speculative investments. With that said, when a substantial player steps up to the plate, it's good to take notice and due some further research into what is really going on here.
What is BrevaGenplus and BrevaGen?
It's a simple swab-based test that help determines the risk of breast cancer. It's the first test of its kind validated to asses both 5-year and lifetime risk for sporadic breast cancer. With early detection assistance from BREVAGen, 95% of these women will have even a stronger chance of survival.
How is this product being accepted in the open market?
From FY2012 Q1 samples received were mere 78, in closing on FY14, samples received in Q4 were 1,096. Which suggest the marketing of the brand from the sales team has gathered some steam, and with BREVAGenplus just released October of 2014, this story is fresh and has plenty of room to gather some momentum.
All these catalyst and more could send this speculative pharma company to new heights. It's important to keep this company on your radar, since it's a low float stock and small catalyst can send this stock roaring back to early January highs.
Disclosure: I am/we are long GENE.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Themes: long-ideas, event-special-situations, new-shareholder-base, speculative, underfollowed Stocks: GENE